The pharmaceutical industry is one of the most important and valuable industries in the world. It is responsible for developing and producing medicines that
improve and save lives. However, there are some things you may not know about this fascinating industry. In this blog post, we will discuss six interesting facts
about the pharmaceutical industry!
1. THE MANUFACTURING PROCESS OF PHARMACEUTICALS IS HIGHLY REGULATED
All pharmaceutical products must go through a rigorous manufacturing process before they can be made available to patients. This process is heavily regulated by
various government agencies to ensure that the medicines are safe and effective. The pharmaceutical manufacturing process usually involves multiple steps, including
the preparation of raw materials, the manufacturing of active pharmaceutical ingredients (APIs), and the packaging and labeling of finished products. To ensure
patient safety, all pharmaceutical companies must adhere to strict regulations set by government agencies such as the Food and Drug Administration (FDA). These
regulations are designed to protect patients by ensuring that medicines are safe and effective.
Diaphragm pumps are positive displacement pumps that use a flexible diaphragm to displace a fluid volume. They're used to move fluids with viscous materials
or solid particles because they can move the fluids without causing damage to the pump. Almost all major industries use diaphragm pumps to move concrete, acid,
and abrasive fluids. Diaphragm pumps use power sources like air pressure, mechanical means, and electricity.
One industry that relies heavily on diaphragm pump operation is the pharmaceutical industry. The diaphragm pump is suitable for the pharmaceutical industry because
it can handle a variety of fluids and provide a gentle flow. This article discusses the various uses of diaphragm pumps in the pharmaceutical industry and how they
have revolutionized it.
1. Filling Vials
Filling vials with liquid medication is a task that has to be accurate and concise. Diaphragm pumps can dispense a precise amount of drugs into a vial. The pump
provides an exact flow rate, ensuring each vial has the correct medication dosage. Diaphragm pumps reduce the risk of medication errors.
As we take look back over the past year and reflect on what we have achieved, it's also important that we look ahead to new challenges and opportunities that
may arise in 2023. We have seen remarkable innovation across the industry in 2022, from big break throughs in treatment and improvements to patient outcomes, to how
the industry is working with big data and technology. But it's fair to say that these achievements came paired with just as many challenges including a continued
talent shortage, hangovers from the pandemic, increasing pressures to innovate and ongoing macroeconomic challenges.
As we head into 2023, I expect these existing challenges to continue alongside new ones, but I also anticipate more opportunities to present themselves. At
Pharamanovia, we predict that the key trends set to catalyse the pharmaceutical and healthcare industries in 2023 include break through innovations, technology,
big data, sustainability, ongoing policy changes and a shift in investment due to inflation.
Utilising big data and tech
Technology has been recognised as one of the industry's biggest tools for many years, and I don't expect to see the pace of how we use technology in healthcare and
pharma to slow down any time soon. In 2023, I expect that we will see further automation in the way we work, with an increase in digital engagement and healthcare
providers leveraging remote access further.
In a rapidly evolving and competitive landscape, the pharmaceutical industry faces unique challenges when it comes to marketing its products and services.
With stringent regulations, complex target audiences, and a need for trust and credibility, pharma companies need to employ effective marketing strategies to stand
out in the crowd. In this blog article, we will explore some key marketing strategies for the pharma industry that can help boost their visibility, engage their
target audience, and drive business growth.
UNDERSTANDING THE UNIQUE LANDSCAPE
The pharma industry operates in a highly regulated environment, where compliance and ethical considerations play a crucial role. Before diving into marketing
strategies, it is essential to have a deep understanding of the industry's dynamics and the target audience. Researching the market, identifying patient needs,
and studying the competitive landscape are vital steps in developing an effective marketing plan.
EMBRACING DIGITAL TRANSFORMATION
Digital transformation has revolutionized marketing across industries, and the pharma sector is no exception. Embracing digital channels and technologies can
significantly enhance the reach and impact of marketing efforts. Pharma companies can leverage social media platforms, create engaging content, and build online
communities to connect with patients, healthcare professionals, and other stakeholders. Implementing robust digital marketing strategies allows for personalized
messaging, real-time communication, and targeted campaigns that resonate with the target audience.
The High Court has dismissed the British Generic Manufacturers Association (BGMA)'s claim on being excluded from ongoing negotiations between the government
and industry to agree a new Voluntary Scheme for medicine pricing and access (VPAS).
The association had sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines
with the Association of the British Pharmaceutical Industry (ABPI) in April.
Commenting on the result of the case, Richard Torbett, Chief Executive of the ABPI said: "For over 60 years the ABPI has acted as the representative industry body
for negotiations on the Voluntary Scheme for branded medicines - a responsibility we take extremely seriously - and one which has been reaffirmed by today's
judgment.
"While we were disappointed that the BGMA decided to take this action - we recognise their decision was driven by the extreme challenge placed on all parts of the
industry from the surge in the branded medicine payment rates.
"The solution to these problems must be a completely new and sustainable approach to medicines provision in the UK which rapidly brings industry revenue payments in
line with comparator countries to unlock investment and growth."
The UK pharmaceutical industry experienced a substantial increase in public trust and favourability during the Covid-19 pandemic, according to a new poll.
This trend appears to be persisting with the study showing a generally favourable view of the sector.
The recent survey, conducted by Ipsos and commissioned by Association of the British Pharmaceutical Industry (ABPI), represents the third instalment in a series
that began in 2021. This ongoing study targets members of the public, healthcare professionals, and parliamentarians.
The study once again underscored a favourable perception of the sector with 67 per cent of respondents recognising that the pharmaceutical industry produces safe
and effective medicines using cutting-edge technologies. Moreover, a majority agrees that it is a highly innovative field.
Seven out of 10 people also trust the sector's readiness to address future pandemics, even as media attention on pharmaceutical companies returns to pre-pandemic
levels. However, concerns arise regarding limitations in accessing new medicines due to cost pressures.
Major Highlights of the Sugar Beet Seeds Market report study:
A detailed look at the global Sugar Beet Seeds Industry
The report analyzes the global Sugar Beet Seeds market and provides its stakeholders with significant actionable insights
The report has considered all the major developments in the recent past, helping the users of the report with recent industry updates
The report study is expected to help the key decision-makers in the industry to assist them in the decision-making process
The study includes data on market intelligence, changing market dynamics, current and expected market trends, etc.
The report comprises an in-depth analysis of macroeconomic and microeconomic factors affecting the global Sugar Beet Seeds market
Market Ecosystem and adoption across market regions
Major trends shaping the global Sugar Beet Seeds market
Historical and forecast size of the Sugar Beet Seeds market in terms of Revenue (USD Million)
Recent industry development and consumer preference trends
Competitive Landscape and player positioning analysis for the global Sugar Beet Seeds market
Key products and solution offerings by major players and business strategies adopted
Recommendations for new market entrants and current players operating in the market space
Analysis of niche and potential segments (type, application, and regions/countries) anticipated to observed promising growth
Key challenges faced by operating players in the market space
Analysis of major risks associated with the market operations
Get FREE PDF Copy @ https://www.marketresearchstore.com/sample/sugar-beet-seeds-market-794502?utm_source=diigo.com-VPL&utm_medium=Varsha
A recent Pharmacists' Defence Association (PDA) survey revealed that 80 per cent of its member working in the NHS in England, Wales, and Northern Ireland
rejected the NHS pay award.
"For the first time in the history of our union, members have told us they are so angry that they would not rule out industrial action in conjunction with other
NHS unions," said Paul Moloney, PDA Union national officer.
"It is important that, whoever is to lead the government, they listen to this message and act now to ensure our members and others in the NHS do not face swinging
cuts to their standard of living."
PDA members were asked whether they would support industrial action if they had rejected the award and if other NHS unions would be taking industrial action. 58 per
cent of those responding said they would support the PDA Union taking industrial action if members of other unions were also planning to take action on this issue.
For now, however, the PDA Union will wait for other unions to publish the outcomes of their own consultations. As a union dedicated to representing the needs of only
pharmacists, the PDA has been able to quickly survey members immediately after the pay award was announced.
The Pharmacists' Defence Association (PDA) has undertaken an additional survey of pharmacists employed in the NHS, before deciding to hold their first-ever
ballot for industrial action.
The PDA has more than 7,000 NHS-employed pharmacists in membership and the union is actively considering balloting those members regarding strike action.
The association said: "The experience of some other unions has shown that the government's restrictive rules, designed to make it difficult for working people to
lawfully take industrial action, means trade unions should test members' strength of feeling before balloting."
"Trade unions are not only forced to rely upon postal ballots, but for lawful industrial action to be taken, the result must also meet three tests- at least 50% of
eligible voters must vote; at least 40% of eligible voters must vote 'yes' and a majority of votes must be for 'yes'."
The association is asking members in England, Northern Ireland and, Wales to show if their collective wish, insignificant enough strength, is for strike action. PDA
has emailed the survey to all its members in the NHS in the three nations and will close on Tuesday 3 January.
The NHS Confederation and the Association of the British Pharmaceutical Industry (ABPI) has published a report that demonstrated the importance of the
collaboration between industry and the NHS to improve patient outcomes across the UK.
Analysis from the report has shown a significant variation in access to innovative medicines for patients across the UK and showed that uptake of new treatments
in these areas continues to be below the average of similar countries in Europe.
The report, 'Transforming Lives, Improving Health Outcomes', has highlighted four initiatives where effective partnerships between the NHS, patient organisations
and industry have helped to tackle unwarranted variation in the uptake of innovative medicines.
Transforming Lives, Improving Health Outcomes also called for a systemwide secondary prevention strategy covering all parts of the health system creating a barrier
to wider and consistent uptake of innovative medicine. It also noted that newly created Integrated Care Systems have the potential to improve preventative treatment.
The report data also showed a 51% variation of uptake of three types of medicines related to diabetes between NHS Trusts in England.
Tricycles are mobility devices that can be custom built for individuals with disabilities that inhibit their ability to ride a typical bike or tricycle.These tricycles offer a multitude of features that can benefit your child or youth, to allow them the joy of bike riding.
Buy online Tricycle For Disabled People at lowest price and cheap cost in india from wheelchair india online shopping store of Tricycle manufacturer, distributor, dealer and supplier of variety of Tricycles at low price in india for handicapped.
Some features include: increased trunk support, rear control steering, assisted pedaling, adjustable handlebars, and foot strapping.
The well known manufacturers and suppliers of Tricycles, which are available in varied sizes and models as per the specific requirements of the clients. We have made the utilization of top class raw materials in fabrication of these tricycles that are well selected and analyzed on set industry norms. Under the leadership and able-support of the industry heads, we have developed our range in compliance with the industry standards.
Features:
Durability
High quality
Optimum strength
The Association of the British Pharmaceutical Industry (ABPI) today released a new guidance to pharmaceutical companies using Disclosure UK which it said will boost transparency in the relationships between healthcare professionals, other relevant decision-makers and the industry.
The guidance encourages companies to use 'Legitimate Interests' as their lawful basis for processing individual's data, in order to increase the number of named healthcare professionals and other individuals on Disclosure UK, the database showing the payments and benefits in kind made by the pharmaceutical industry to doctors,nurses and other health professionals and organizations.
"I'm pleased the ABPI is launching this new guidance which will boost patient safety and public confidence in our healthcare professionals," Patient Safety and Primary Care Minister Maria Caulfield commented.
Pharmaceutical companies AbbVie and Eli Lilly have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday.
Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global boardrooms and investors as repayment rates in
2023 have surged to 26.5 per cent of revenue, the Association of the British Pharmaceutical Industry (ABPI) said in a statement.
"The current scheme has harmed innovation, with costs spiralling out of control, and the UK falling behind other major countries to be left as a global outlier,"
said Laura Steele, president and general manager for Eli Lilly's Northern Europe division.
ABPI said it was seeking early talks with the government to set out a new future settlement.
In December, the industry body had said the government raised the amount manufacturers of branded medicines within the voluntary scheme will be required to return
to almost £3.3 billion in sales revenue from an earlier amount of £1.8 billion.
The British Generic Manufacturers Association (BGMA) has elected Diane DiGangi Trench to be its new vice-chair.
DiGangi Trench takes up the position replacing Xiromed's Peter Ballard and in 12-months' time will assume the association's chair role from Accord's Peter Kelly.
With over 25 years of pharmaceutical industry experience, DiGangi Trench has held a number of senior commercial roles including stints with Takeda and Astra Zeneca.
She joined Sandoz in 2018 in the US, where she served as Vice-President, Market Access and Patient Services.
In 2021, she became the head of Sandoz' UK business and in her two years in role, she has led the organisation through a post-COVID recovery and growth phase to
prepare for the proposed spin out of the company from its parent, Novartis, expected later this year.
She said: "It's a great honor to take on the role of Vice Chair of the BGMA. The success of the generics and biosimilar industry is essential to the functioning of
the NHS. Generic medicines fill four out of five UK prescriptions and biosimilars enable the NHS to expand access to more patients. I am passionate about increasing
the sustainability of our industry so we can continue to play our vital part in the health of the nation."
Mark Samuels, BGMA chief executive, said: "We are extremely fortunate to be able to call upon the expertise of Diane who has already added significant value through
her role on the BGMA board and leadership of a key strategic committee.
An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights
for Covid-19 interventions between the pharmaceutical industry and developing nations endures.
At the heart of the plan is a commitment to set aside part of the production of vaccines and treatments upfront for vulnerable populations in low-income countries
when the next pandemic arises, given how fragmented access to Covid tools has left many populations unprotected.
In order to do better next time - and without knowing which companies will develop the first drugs and vaccines for the next pandemic - having the industry
collectively make this commitment is potentially transformative, said Thomas Cueni, head of the International Federation of Pharmaceutical Manufacturers &
Associations (IFPMA).
The pledge, called the Berlin Declaration, was made on July 19 by members of the global pharmaceutical industry group that include many of the companies involved
in developing Covid interventions, such as AstraZeneca, GSK, Moderna, Pfizer and Merck.
The declaration is not legally binding.
However, if a company that signed on reneges on its vow, it would face grave consequences in the court of public opinion, said Cueni.
The only way to overcome the challenges facing the medicines supply chain in the UK is through close cooperation - the government, pharmacies, and the
industry all working together in tandem - said Andrew Stephenson, Minister for Health and Social Care.
The MP for Pendle, Lancashire made the statement while addressing the Healthcare Distribution Association's (HDA) Annual Conference at the Institute of Directors
in Pall Mall, London on Thursday (25 January), where over 130 leaders from the pharma industry gathered.
As the keynote speaker, Stephenson acknowledged the crucial role wholesalers, manufacturers, and retail pharmacy chains, play in the wellbeing of the nation.
He said: "In the first few months that I've been in this job, it's become immediately obvious to me just how important this sector is and just how important the
work that all of you do is for our country."
"The UK remains genuinely world-leading for life sciences in numerous areas - yet we continue to underperform on our potential," said Richard Torbett, Chief
Executive of the Association of the British Pharmaceutical Industry (ABPI).
His statement is based on recent government data indicating that the UK is not fully capitalizing on its strong historical and institutional advantages in life
sciences across a range of economic, health, and research indicators.
The latest 'Life sciences competitiveness indicators 2024' report from the government's Office for Life Sciences revealed that while the pharmaceutical industry
leads in R&D spending with £9 billion in 2022, representing a fifth of total business investment, the country saw a notable decline in foreign direct
investment (FDI), industry clinical trials, and exports.
In 2023, FDI dropped by 21 per cent to £0.8 billion, following a trend that saw a 52 per cent decrease over the previous two years, including a £0.9 billion fall
in FDI the year prior.
In the pharmaceutical industry, maintaining high standards for water quality is crucial for ensuring product safety, efficacy, and compliance with
regulatory standards.
Water is a fundamental ingredient in drug manufacturing, and its quality directly impacts the production process and the end products. This makes adherence
to water service compliance a legal obligation and a critical aspect of operational integrity.
THE LEGAL COMPLICATIONS OF POOR WATER QUALITY
Compliance with water quality standards in the pharmaceutical industry is mandated by regulatory agencies such as the MHRA, several regulations that set
strict criteria for the types of water used, including purified water, water for injection, and sterile water.
Failure to meet these standards can result in severe penalties, including product recalls, fines, and loss of manufacturing licenses. Regulatory compliance
ensures the pharmaceutical companies adhere to legislations and avoid legal repercussions that can damage their reputation and financial standing
Do you know that Bottled water industry in India is worth more than 10,000 crores and is growing faster than the carbonated drinks industry? You might have a feeling that you are getting pure mineral water when you buy a bottle of water, but,
IS IT REALLY SAFE?
The medical diagnostics industry is advancing at a fast-paced. The new innovations come with a promise to enhance the accuracy of detecting diseases...